Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Evgeny Degtyarev"'
Autor:
Yanni Hao, Wei-Chun Hsu, Craig S Parzynski, Evgeny Degtyarev, Lisa V Hampson, Aisha Masood, Wen-Hsing Wu
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 7 (2023)
Aim: To contextualize the effectiveness of tisagenlecleucel versus real-world standard of care (SoC) in relapsed/refractory follicular lymphoma. Materials & methods: A retrospective indirect matched comparison study using data from the phase II ELA
Externí odkaz:
https://doaj.org/article/2e68b7b1092c4873bb523cd37838a9af
Autor:
Rachael Lawrance, Evgeny Degtyarev, Philip Griffiths, Peter Trask, Helen Lau, Denise D’Alessio, Ingolf Griebsch, Gudrun Wallenstein, Kim Cocks, Kaspar Rufibach
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 4, Iss 1, Pp 1-8 (2020)
Abstract Background Published in 2019, a new addendum to the ICH E9 guideline presents the estimand framework as a systematic approach to ensure alignment among clinical trial objectives, trial execution/conduct, statistical analyses, and interpretat
Externí odkaz:
https://doaj.org/article/3b5822f5bed34085bce0c320c49936e6
Autor:
Rajeshwari Sridhara, Elizabeth Barksdale, Olga Marchenko, Qi Jiang, Yuki Ando, Erick Bloomquist, Michael Coory, Melissa Crouse, Evgeny Degtyarev, Theodor Framke, Boris Freidlin, David E. Gerber, Thomas Gwise, Filip Josephson, Lorenzo Hess, Paul Kluetz, Daniel Li, Sumithra Mandrekar, Martin Posch, Khadija Rantell, Bohdana Ratitch, Andrew Raven, Kit Roes, Kaspar Rufibach, Sinan B. Sarac, Richard Simon, Harpreet Singh, Marc Theoret, Andrew Thomson, Emmanuel Zuber, Yuan Li Shen, Richard Pazdur
Publikováno v:
Statistics in Biopharmaceutical Research. 15:444-449
Autor:
Richard T. Maziarz, Jie Zhang, Hongbo Yang, Xinglei Chai, Chengbo Yuan, Elisabeth Schwarz, Mihael Jakovac, Marcela Martinez-Prieto, Abhijit Agarwal, Evgeny Degtyarev, Constantine Tam, Gilles Salles
Publikováno v:
Blood Advances. 6:2536-2547
No head-to-head trials have compared the efficacy of tisagenlecleucel vs historical treatments for adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This study indirectly compared the overall survival (OS) and overall resp
Publikováno v:
Statistics in Biopharmaceutical Research. 15:23-26
We congratulate the authors of this landscape assessment on a comprehensive and stimulating article which carefully reviews many important biostatistical issues related to the use of real-world dat...
Autor:
Emily Butler, Susan Halabi, Alain Ravaud, Evgeny Degtyarev, Robert J. Motzer, Michelle Casey, Paola Aimone, Oliver Sailer, Rui Tang, Daniel J. George, Maria Jose Lechuga, Feng Liu, Viktoriya Stalbovskaya
Publikováno v:
Pharmaceutical Statistics. 20:324-334
The estimand framework requires a precise definition of the clinical question of interest (the estimand) as different ways of accounting for "intercurrent" events post randomization may result in different scientific questions. The initiation of subs
Autor:
Michael R. Bishop, Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, Anna Sureda, Richard Greil, Catherine Thieblemont, Franck Morschhauser, Martin Janz, Ian Flinn, Werner Rabitsch, Yok-Lam Kwong, Marie J. Kersten, Monique C. Minnema, Harald Holte, Esther H.L. Chan, Joaquin Martinez-Lopez, Antonia M.S. Müller, Richard T. Maziarz, Joseph P. McGuirk, Emmanuel Bachy, Steven Le Gouill, Martin Dreyling, Hideo Harigae, David Bond, Charalambos Andreadis, Peter McSweeney, Mohamed Kharfan-Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin
Publikováno v:
New England Journal of Medicine, 386(7), 629-639. Massachussetts Medical Society
New England journal of medicine, 386(7), 629-639. Massachussetts Medical Society
Bishop, M R, Dickinson, M, Purtill, D, Barba, P, Santoro, A, Hamad, N, Kato, K, Sureda, A, Greil, R, Thieblemont, C, Morschhauser, F, Janz, M, Flinn, I, Rabitsch, W, Kwong, Y-L, Kersten, M J, Minnema, M C, Holte, H, Chan, E H L, Martinez-Lopez, J, Müller, A M S, Maziarz, R T, McGuirk, J P, Bachy, E, Gouill, S L, Dreyling, M, Harigae, H, Bond, D, Andreadis, C, McSweeney, P, Kharfan-Dabaja, M, Newsome, S, Degtyarev, E, Awasthi, R, del Corral, C, Andreola, G, Masood, A, Schuster, S J, Jäger, U, Borchmann, P & Westin, J R 2022, ' Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma ', New England Journal of Medicine, vol. 386, no. 7, pp. 629-639 . https://doi.org/10.1056/NEJMoa2116596
New England journal of medicine, 386(7), 629-639. Massachussetts Medical Society
Bishop, M R, Dickinson, M, Purtill, D, Barba, P, Santoro, A, Hamad, N, Kato, K, Sureda, A, Greil, R, Thieblemont, C, Morschhauser, F, Janz, M, Flinn, I, Rabitsch, W, Kwong, Y-L, Kersten, M J, Minnema, M C, Holte, H, Chan, E H L, Martinez-Lopez, J, Müller, A M S, Maziarz, R T, McGuirk, J P, Bachy, E, Gouill, S L, Dreyling, M, Harigae, H, Bond, D, Andreadis, C, McSweeney, P, Kharfan-Dabaja, M, Newsome, S, Degtyarev, E, Awasthi, R, del Corral, C, Andreola, G, Masood, A, Schuster, S J, Jäger, U, Borchmann, P & Westin, J R 2022, ' Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma ', New England Journal of Medicine, vol. 386, no. 7, pp. 629-639 . https://doi.org/10.1056/NEJMoa2116596
BACKGROUND: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for dif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d15c5a71064f7018247c023fe0a84bb
https://research.vumc.nl/en/publications/05692014-3989-41b0-9670-0dae99bc18df
https://research.vumc.nl/en/publications/05692014-3989-41b0-9670-0dae99bc18df
Autor:
Kapildeb Sen, Frank Bretz, Evgeny Degtyarev, Yiyun Zhang, Bjoern Bornkamp, Lisa V. Hampson, David Lebwohl, Mouna Akacha, Antonella Maniero, Emmanuel Zuber
Publikováno v:
JCO precision oncology. 3
The diversity of patient journeys can raise fundamental questions regarding the evaluation of drug effects in clinical trials to inform clinical practice. When defining the treatment effect of interest in a trial, the researcher needs to account for
Autor:
Yue Shentu, Godwin Yung, Kaspar Rufibach, Steven Sun, Feng Liu, Oliver Sailer, Jonathan Siegel, Yi Liu, Rui Tang, Evgeny Degtyarev, Michelle Casey, Stefan Englert, Jiangxiu Zhou
Publikováno v:
Statistics in Biopharmaceutical Research
article-version (VoR) Version of Record
article-version (VoR) Version of Record
–Coronavirus disease 2019 (COVID-19) outbreak has rapidly evolved into a global pandemic. The impact of COVID-19 on patient journeys in oncology represents a new risk to interpretation of trial results and its broad applicability for future clinica
Autor:
Emily Martin, Godwin Yung, Juliane Manitz, Mindy Mo, Rui Sammi Tang, Vincent Haddad, Kaspar Rufibach, Fei Jie, Hannes Buchner, Jyotirmoy Dey, Marie-Laure Casadebaig, Jiangxiu Zhou, Natalia Kan-Dobrosky, Yue Shentu, Viktoriya Stalbovskaya, Evgeny Degtyarev
Publikováno v:
Pharmaceutical statisticsREFERENCES. 21(1)
An addendum of the ICH E9 guideline on Statistical Principles for Clinical Trials was released in November 2019 introducing the estimand framework. This new framework aims to align trial objectives and statistical analyses by requiring a precise defi